Patheon Announces A Change To Its Management Structure
TORONTO, Nov. 1, 2011 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that Eric Evans, Patheon's Executive Vice President and Chief Financial Officer, has resigned from the company.
"Mr. Evans has helped to guide the creation and development of a company strategy which is aimed at continuing our focus on customer service, quality, scientific excellence and a commitment toward improving both top line and bottom line growth. The Board and I thank Eric for his considerable contributions to Patheon and wish him every success in the future" stated Jim Mullen, CEO of Patheon.
Mullen continued, "Patheon is already seeing progress towards execution of its new company strategy announced in September with specific focus on efforts to further enhance capacity and look at costs. We have commenced a search for our new CFO."
Until a new CFO has been appointed, Mr. Evan's duties will be managed by Patheon's existing finance and operations teams.About Patheon Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. The company's integrated development and manufacturing network of 10 facilities, nine development centers and one clinical trial packaging facility across North America and Europe, ensures that customer products can be launched with confidence anywhere in the world. SOURCE Patheon Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV